Articles From: Align Technology Announces Second Quarter 2014 Results to Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder


-- Record revenues of $192.5 million, up 17.5% year-over-year --
Sign-up for Align Technology Announces Second Quarter 2014 Results investment picks
http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1140009&ProfileId=051205&sourceType=1 SAN JOSE, CA --
Sign-up for Align Technology Announces Shareholder Class Action Lawsuit Dismissed With Prejudice investment picks
http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1126049&ProfileId=051205&sourceType=1 SAN JOSE, CA --
Sign-up for Align Technology Binding Corporate Rules Approved investment picks
http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1140967&ProfileId=051205&sourceType=1 SAN JOSE, CA --
Sign-up for Align Technology to Present at Upcoming Financial Conferences investment picks
http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1130631&ProfileId=051205&sourceType=1 SAN JOSE, CALIFORNIA, and AMSTERDAM, THE NETHERLANDS --
Sign-up for Align Technology Wins Top International Healthcare Communications Award With Invisalign Smile Campaign investment picks
2014/9/3
Alimentation Couche-Tard announces its results for its first quarter of fiscal year 2015 Canada NewsWire Overview of the First Quarter of Fiscal 2015 Statoil Fuel & Retail Period results Our results for the 12-week period ended July 20, 2014 include those of Statoil Fuel & Retail for the period beginning May 1 st , 2014 and ending July 20, 2014 , resulting in a period of 81 days.
Sign-up for Alimentation Couche-Tard announces its results for its first quarter of fiscal year 2015 investment picks
2014/9/3
Record net earnings of $269.5 million ( $0.47 per share on a diluted basis) for the first quarter of fiscal 2015.
Sign-up for Alimentation Couche-Tard announces its results for its first quarter of fiscal year 2015 investment picks
2014/7/7
Alimentation Couche-Tard announces its results for its fourth quarter and fiscal year 2014 Canada NewsWire Fiscal year 2014 For fiscal 2014, diluted net earnings per share adjusted for non-recurring items of US$1.35 compared with US$1.11 for fiscal 2013, up 21.6%. Three-for-one split of all of the Corporation's issued and outstanding Class "A" and "B" shares effective April 14, 2014 .
Sign-up for Alimentation Couche-Tard announces its results for its fourth quarter and fiscal year 2014 investment picks
2014/7/7
Fiscal year 2014 For fiscal 2014, diluted net earnings per share adjusted for non-recurring items of US$1.35 compared with US$1.11 for fiscal 2013, up 21.6%. Three-for-one split of all of the Corporation's issued and outstanding Class "A" and "B" shares effective April 14, 2014 .
Sign-up for Alimentation Couche-Tard announces its results for its fourth quarter and fiscal year 2014 investment picks
2014/7/29
LAVAL, QC , July 29, 2014 /PRNewswire/ - Alimentation Couche-Tard Inc. (hereinafter referred to as " Couche-Tard ") (TSX: ATD.A ATD.B) announces today that it has signed, through its wholly-owned indirect subsidiary, Mac's Convenience Stores LLC, an agreement to acquire 55 stores and related assets from Tri Star Marketing, Inc. and affiliates (hereinafter collectively referred to as the " Parties ") of which 51 stores located in the state of Illinois and four stores located in the state of Indiana .
Sign-up for Alimentation Couche-Tard Inc. acquires 55 Stores in the state of Illinois and state of Indiana investment picks
ILUVIEN® Injections Increased over 25% in the United Kingdom on Sequential Basis from First Quarter 2014 Alimera Will Host a Conference Call at 4:30 PM ET Today ATLANTA , Aug.
Sign-up for Alimera Sciences Reports Second Quarter 2014 Financial Results investment picks
ATLANTA , July 24, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its second quarter of fiscal year 2014 financial results after the market close on Thursday, August 7, 2014 .
Sign-up for Alimera Sciences To Release Second Quarter 2014 Results investment picks
ATLANTA , July 31, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Danish Health and Medicines Authority has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Sign-up for Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Denmark For The Treatment Of Chronic Diabetic Macular Edema investment picks
ATLANTA , June 23, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Sign-up for Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Italy For The Treatment Of Chronic Diabetic Macular Edema investment picks
Portugal approves reimbursement for ILUVIEN ATLANTA , July 28, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Norwegian Medicines Evaluation Board has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Sign-up for Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Norway For The Treatment Of Chronic Diabetic Macular Edema investment picks
ATLANTA , June 30, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the positive outcome of the Repeat-Use Procedure for ILUVIEN® for the treatment of chronic diabetic macular edema (DME) in an additional 10 European Union countries.
Sign-up for Alimera Sciences' ILUVIEN® Receives Positive Outcome Of Repeat-Use Procedure For 10 Additional European Countries investment picks
Sweden is latest country to grant marketing authorization ATLANTA , Sept.
Sign-up for Alimera Sciences' ILUVIEN® Receives Tenth National Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema investment picks
NEW YORK, N.Y., June 30, 2014 (GLOBE NEWSWIRE) -- AlixPartners, the global business advisory firm, and Career Education Corporation (NASDAQ: CECO) , a provider of postsecondary education programs and services, have been honored by the Global M &A Network, sharing the organization's Turnaround Atlas Award for "Corporate Turnaround of the Year: Middle Markets" and "Team of the Year." The AlixPartners team was led by Darin Facer and Keith Gillespie, managing directors in the firm's Enterprise Improvement group.
Sign-up for AlixPartners and Career Education Corporation Honored by Global M&A Network for Corporate Turnaround Success investment picks
http://media.marketwire.com/attachments/201307/170375_AWC-logo-small.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1126603&ProfileId=051205&sourceType=1 SCOTTSDALE, AZ --
Sign-up for Alkaline Water Co. Available Now at H-E-B Latest Store Launch in San Antonio investment picks
http://media.marketwire.com/attachments/201307/170375_AWC-logo-small.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1133331&ProfileId=051205&sourceType=1 SCOTTSDALE, AZ --
Sign-up for Alkaline Water Co. Begins Outdoor Ad Campaign in Southern California investment picks
http://media.marketwire.com/attachments/201307/170375_AWC-logo-small.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1125492&ProfileId=051205&sourceType=1 SCOTTSDALE, AZ --
Sign-up for Alkaline Water Co. Joins With Associated Grocers of Baton Rouge, Louisiana to Serve Southern States as Summer Heats Up investment picks
http://media.marketwire.com/attachments/201307/170375_AWC-logo-small.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1143873&ProfileId=051205&sourceType=1 SCOTTSDALE, AZ --
Sign-up for Alkaline Water Co. Now at Select Whole Foods Markets in Arizona investment picks
SCOTTSDALE, Ariz., July 24, 2014 (GLOBE NEWSWIRE) -- The Alkaline Water Company Inc. (OTCBB:WTER) (the "Company"), developers of an innovative state of the art proprietary electrolysis beverage process, packaged and sold in 3 liter and 1 gallon sizes under the trade name Alkaline88, announced today another success for its ongoing national expansion program with acceptance for placement at FoodMaxx Supermarkets ( www.foodmaxx.com ). FoodMaxx is a 45 store warehouse market concept owned by Save Mart Supermarkets.
Sign-up for Alkaline Water Co. Products Now Available at FoodMaxx Maximum Discount Supermarkets investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G018664-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/7/22/11G018664/170375_AWC-logo-small-1387439793977.jpg SCOTTSDALE, AZ--(Marketwired - July 22, 2014) - The Alkaline Water Company Inc. (OTCBB: WTER) (the "Company"), developers of an innovative state of the art proprietary electrolysis beverage process, packaged and sold in 3 liter and 1 gallon sizes under the trade name Alkaline88, is extremely pleased to announce that its ongoing national expansion program has reached an all new level of product placement with entry into a broker agreement via M3, Inc that launches sales of Alkaline88 directly into the military retail supply chain.
Sign-up for Alkaline Water Co. to Hit Military Retail Shelves With M3 Broker Agreement investment picks
http://media.marketwire.com/attachments/201307/170375_AWC-logo-small.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1128014&ProfileId=051205&sourceType=1 SCOTTSDALE, AZ --
Sign-up for Alkaline Water Company Reports Fourth Quarter and Fiscal Year 2014 Financial Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1124781&ProfileId=051205&sourceType=1 LAS VEGAS, NV --
Sign-up for Alkame Launches 100% Fluoride-Free Premium Drinking Water for Infants and Children investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1135051&ProfileId=051205&sourceType=1 LAS VEGAS, NV --
Sign-up for Alkame Water 20 Oz. Bottle Now Available Nationwide Direct-to-Consumer Through Amazon.com With Free Shipping investment picks
Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in a phase 2 study of ALKS 3831, an investigational, novel, oral, broad-spectrum atypical antipsychotic medicine in development for the treatment of schizophrenia.
Sign-up for Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic investment picks
Alkermes plc (NASDAQ: ALKS) today announced the initiation of FORWARD-5, the third of three core efficacy studies planned in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The study will evaluate the efficacy and safety of ALKS 5461 in patients suffering from MDD who have had an inadequate response to commonly prescribed drugs for depression, including selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Approximately two-thirds of patients who are diagnosed with MDD do not adequately respond to initial antidepressant therapy.
Sign-up for Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Align Technology Announces Second Quarter 2014 Results to Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices